Loading...
•
Aug 31, 2021
AngioDynamics Q1 2022 Earnings Report
AngioDynamics experienced revenue growth and gross margin improvement, but reported a net loss and adjusted loss per share.
Key Takeaways
AngioDynamics reported a 9.6% increase in net sales compared to the prior-year quarter, driven by Med Tech growth. However, the company reported a net loss of $7.0 million, or $0.18 per share, and an adjusted loss per share of $0.02. The gross margin increased by 120 basis points year over year.
Net sales increased by 9.6% compared to the prior-year quarter.
Gross margin improved by 120 basis points year over year.
GAAP loss per share was $0.18, and adjusted loss per share was $0.02.
The company commenced a limited market release of its AlphaVac Mechanical Thrombectomy device in September.
AngioDynamics
AngioDynamics
AngioDynamics Revenue by Segment
AngioDynamics Revenue by Geographic Location
Revenue by Segment
Med Tech Revenue
CapyFin.comMed Device Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
The Company now expects its fiscal year 2022 net sales to be in the range of $310 to $315 million, an increase from its prior guidance of $305 to $310 million. The Company expects gross margin to be approximately 55.0% and adjusted earnings per share in the range of $0.00 to $0.05 as it continues to invest in new product launches to drive future growth.
Revenue & Expenses
Visualization of income flow from segment revenue to net income